Skip to content

Combating Opioid Dependence

Combating Opioid Dependence

The opioid epidemic is a hot topic across the United States, along with the alternatives that could alleviate the tragic consequences the epidemic brings. Opioids, also known as narcotics, are strong prescription pain relievers such as oxycodone, hydrocodone and fentanyl. Although illegal, heroin is also considered to be an opioid. Most patients are introduced to these strong narcotics after a major injury or surgery and should only use them on a short-term basis. Unfortunately, this short-term timeline is not always followed, and the patient can become dependent on the pain killers for everyday life.

Understanding Opioid Dependence

Every day, more than 130 people in the United States die from an opioid overdose – including prescription pain relievers, heroin and synthetics. See below for additional facts we’ve uncovered regarding the opioid crisis:

  • Roughly 21-29% of patients prescribed opioids for chronic pain misuse them
  • Between 8-12% develop an opioid use disorder
  • An estimated 4-6% who misuse prescription opioids transition to heroin
  • About 80% of people who use heroin first misused prescription opioids

Ultimately, the opioid epidemic has become a severe national crisis that affects public health as well as social and economic welfare. Not only does the devastating issue carry consequences like an increase in opioid misuse and related overdoses, it’s also a catalyst for neonatal abstinence syndrome due to opioid use during pregnancy. As more opioid users turn to something stronger, like heroin, an increase in injection drug use follows, contributing to the spread of infectious diseases such as HIV and hepatitis C.

A Better Option

Both prescription opioids and cannabis have the same primary use: analgesia – the inability to feel pain. Currently, up to 90% of patients in state-level medical cannabis registries list chronic pain as their qualifying condition. According to a review conducted by the National Academies of Science and Medicine, when given access to cannabis, patients currently using opioids for chronic pain decreased their use by 40-60% and reported that they prefer cannabis rather than opioids. Patients also reported fewer side effects with cannabis and a better quality of life compared to opioids. 

Although there is minimal clinical literature that supports the use of cannabis as a treatment for acute pain, there is a long-standing body of pre-clinical evidence that demonstrates the effectiveness of cannabinoids in providing a pain-free life in drug-naïve animals.

“The mechanisms of cannabinoid antinociception are remarkably similar to those of opioid analgesics. Both the CB1 and MOR are G-protein coupled receptors, and agonist-initiated disinhibition of GABA release in the descending pain pathway is just one example of overlapping antinociceptive mechanisms between these drugs.” -NCBI.gov

The evidence we do have that supports the role of cannabis in acute, nonsevere pain management could lead to a substantial reduction in opioid prescription use. This increase in medical marijuana use for treating acute pain could eliminate patients being exposed to the risks of opioid dose escalation and physical dependence. We still have a long way to go, but the potential impact of this therapy definitely warrants further exploration of the efficacy of cannabis for pain relief and eliminating opioid dependence.

Interested in learning more about medical cannabis efficacies for opioid dependence or other qualifying conditions? Join Arfinn Med for FREE today to access HIPAA compliant peer-to-peer data on medical marijuana treatment efficacies, discuss treatment plans with other licensed physicians and stay up-to-date on all of the latest industry findings.

Sources: https://medlineplus.gov/healthtopics/opioidabuseandaddiction_b.html?utm_expid=.YDctbaKlRwemM6rjn-4YCA.2&utm_referrer=https%3A%2F%2Fwww.google.com%2F

https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135562/

Stories you may be interested in

Medical Marijuana Faces Acceptance Barrier by Hesitant Medical Schools

A new study shows a growing interest by university pharmacy programs in teaching about medical marijuana in their curriculum, while medical schools seem to lag behind. Sixty-two percent of U.S. pharmacy school respondents queried in a new survey said they included medical marijuana in their doctorate of pharmacy curriculum. That’s according to a nine-page study co-authored by…
Read More

You Can Get A Master’s In Medical Cannabis In Maryland

Summer Kriegshauser is one of 150 students in the inaugural class of the University of Maryland, Baltimore’s Master of Science in Medical Cannabis Science and Therapeutics, the first graduate program of its type in the country. This will be Kriegshauser’s second master’s degree and she hopes it will offer her a chance to change careers. “I…
Read More

THC vs. CBD: What You Need to Know

With the rising demand of natural medicines, medical marijuana compounds THC and CBD are starting to make a name for themselves more than ever before. These two compounds have a wide range of health benefits, making it understandable why patients and physicians would be interested in this alternative treatment option. Although these two compounds are…
Read More

Data Migration During EMR Changes

One of the most challenging aspects when deciding to switch to a new EMR system is how to get existing data from the old system to the new system safely, securely and accurately.  Many times, the scope of this task is enough to force providers to remain with a subpar vendor even though there are…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

Former Detroit Lions players announce partnership with Harvard to study marijuana

Former Detroit Lions football players Calvin Johnson and Robert Sims are expanding their emerging cannabis enterprise into the field of medicine. The pair announced an agreement Thursday with the International Phytomedicines and Medical Cannabis Institute at Harvard University, which is researching the benefits of medical marijuana and looking at the best ways to deliver cannabis-based…
Read More

Leave a Comment

You must be logged in to post a comment.